More Than Fat in the Liver: Understanding the Metabolic Impact of MASLD and MASH

This program explores the risks associated with MASLD/MASH, why early screening for liver fibrosis is needed in at-risk patients like those with obesity, and why metabolic drivers should be addressed as part of MASH care.

Industry Supporter: Boehringer Ingelheim Pharmaceuticals, Inc.